Tim Rolph

4.8k total citations · 5 hit papers
43 papers, 2.6k citations indexed

About

Tim Rolph is a scholar working on Molecular Biology, Animal Science and Zoology and Epidemiology. According to data from OpenAlex, Tim Rolph has authored 43 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Molecular Biology, 9 papers in Animal Science and Zoology and 9 papers in Epidemiology. Recurrent topics in Tim Rolph's work include Fibroblast Growth Factor Research (15 papers), Kruppel-like factors research (11 papers) and Liver Disease Diagnosis and Treatment (9 papers). Tim Rolph is often cited by papers focused on Fibroblast Growth Factor Research (15 papers), Kruppel-like factors research (11 papers) and Liver Disease Diagnosis and Treatment (9 papers). Tim Rolph collaborates with scholars based in United States, United Kingdom and Denmark. Tim Rolph's co-authors include Erik J. Tillman, C T Jones, Stephen A. Harrison, Veena Somayaji, Saswata Talukdar, Roberto A. Calle, Brittany de Temple, Kitty Yale, Guy Neff and Andrew Cheng and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Nature Medicine.

In The Last Decade

Tim Rolph

41 papers receiving 2.5k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A Long-Acting FGF21 Molecule, PF-05231023, Decreases Body Weight and Improves Lipid Profile in Non-human Primates and Type 2 Diabetic Subjects

2016 406 citations Saswata Talukdar, Yingjiang Zhou et al. profile →
Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial

2021 255 citations Stephen A. Harrison, Peter Ruane et al. Nature Medicine profile →
Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial

2023 146 citations Stephen A. Harrison, Juan P. Frías et al. The Lancet. Gastroenterology & hepatology profile →
FGF21 agonists: An emerging therapeutic for metabolic dysfunction-associated steatohepatitis and beyond

2024 68 citations Stephen A. Harrison, Tim Rolph et al. Journal of Hepatology profile →
Efruxifermin in Compensated Liver Cirrhosis Caused by MASH

2025 19 citations Mazen Noureddin, Guy Neff et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Tim Rolph United States	25	1.4k	795	535	477	298	43	2.6k
Takashi Goto Japan	22	1.4k 1.0×	967 1.2×	619 1.2×	533 1.1×	342 1.1×	92	3.0k
Jennifer Altomonte Germany	26	1.8k 1.3×	693 0.9×	845 1.6×	697 1.5×	876 2.9×	52	3.6k
Debby P.Y. Koonen Netherlands	31	2.0k 1.5×	1.2k 1.5×	1.2k 2.3×	617 1.3×	633 2.1×	53	3.9k
J. J. Spitzer United States	28	574 0.4×	450 0.6×	782 1.5×	329 0.7×	390 1.3×	113	2.5k
Tahar Hajri United States	23	1.1k 0.8×	438 0.6×	770 1.4×	281 0.6×	353 1.2×	56	2.1k
Delphine Eberlé France	20	988 0.7×	585 0.7×	600 1.1×	234 0.5×	616 2.1×	36	2.5k
Haiming Cao United States	22	2.2k 1.7×	1.2k 1.6×	1.4k 2.6×	399 0.8×	449 1.5×	40	4.3k
Yuren Wei United States	26	787 0.6×	1.3k 1.6×	720 1.3×	708 1.5×	428 1.4×	52	2.6k
Ming Yin United States	24	1.0k 0.8×	1.3k 1.6×	263 0.5×	377 0.8×	297 1.0×	36	3.1k
Yii‐Der I. Chen United States	25	549 0.4×	539 0.7×	421 0.8×	629 1.3×	259 0.9×	57	2.0k

Countries citing papers authored by Tim Rolph

Since Specialization

Citations

This map shows the geographic impact of Tim Rolph's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tim Rolph with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tim Rolph more than expected).

Fields of papers citing papers by Tim Rolph

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tim Rolph. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tim Rolph. The network helps show where Tim Rolph may publish in the future.

Co-authorship network of co-authors of Tim Rolph

This figure shows the co-authorship network connecting the top 25 collaborators of Tim Rolph. A scholar is included among the top collaborators of Tim Rolph based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tim Rolph. Tim Rolph is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Noureddin, Mazen, Juan P. Frías, Guy Neff, et al.. (2025). Safety and efficacy of once-weekly efruxifermin versus placebo in metabolic dysfunction-associated steatohepatitis (HARMONY): 96-week results from a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial. The Lancet. 406(10504). 719–730. 5 indexed citations

Lucas, Kathryn Jean, Doreen Chan, Erik J. Tillman, et al.. (2024). 897-P: Insulin-Sensitizing Effects of Efruxifermin Improve Glycemic Control in Patients with MASH and Type 2 Diabetes. Diabetes. 73(Supplement_1). 1 indexed citations

Shumbayawonda, Elizabeth, Anneli Andersson, Kitty Yale, et al.. (2024). Decreases in cT1 and liver fat content reflect treatment-induced histological improvements in MASH. Journal of Hepatology. 82(3). 438–445. 14 indexed citations

Harrison, Stephen A., Juan P. Frías, Kathryn Jean Lucas, et al.. (2024). Safety and Efficacy of Efruxifermin in Combination With a GLP-1 Receptor Agonist in Patients With NASH/MASH and Type 2 Diabetes in a Randomized Phase 2 Study. Clinical Gastroenterology and Hepatology. 23(1). 103–113. 37 indexed citations

Harrison, Stephen A., et al.. (2024). FGF21 agonists: An emerging therapeutic for metabolic dysfunction-associated steatohepatitis and beyond. Journal of Hepatology. 81(3). 562–576. 68 indexed citations breakdown →

Tillman, Erik J., Sanofar Abdeen, Derrick E. Johnson, et al.. (2023). Noncompetitive immunoassay optimized for pharmacokinetic assessments of biologically active efruxifermin. Journal of Pharmaceutical and Biomedical Analysis. 232. 115402–115402. 6 indexed citations

Harrison, Stephen A., Juan P. Frías, Guy Neff, et al.. (2023). Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial. The Lancet. Gastroenterology & hepatology. 8(12). 1080–1093. 146 indexed citations breakdown →

Harrison, Stephen A., Peter Ruane, B. Freilich, et al.. (2022). A randomized, double-blind, placebo-controlled phase IIa trial of efruxifermin for patients with compensated NASH cirrhosis. JHEP Reports. 5(1). 100563–100563. 72 indexed citations

Harrison, Stephen A., Peter Ruane, B. Freilich, et al.. (2021). Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial. Nature Medicine. 27(7). 1262–1271. 255 indexed citations breakdown →

10.

Abuqayyas, Lubna, et al.. (2020). AKR-001, an Fc-FGF21 Analog, Showed Sustained Pharmacodynamic Effects on Insulin Sensitivity and Lipid Metabolism in Type 2 Diabetes Patients. Cell Reports Medicine. 1(4). 100057–100057. 102 indexed citations

11.

Tillman, Erik J. & Tim Rolph. (2020). FGF21: An Emerging Therapeutic Target for Non-Alcoholic Steatohepatitis and Related Metabolic Diseases. Frontiers in Endocrinology. 11. 601290–601290. 151 indexed citations

12.

Lintner, Nathanael G., Kim F. McClure, Donna N. Petersen, et al.. (2017). Selective stalling of human translation through small-molecule engagement of the ribosome nascent chain. PLoS Biology. 15(3). e2001882–e2001882. 94 indexed citations

13.

White, Phillip J., Amanda L. Lapworth, Jie An, et al.. (2016). Branched-chain amino acid restriction in Zucker-fatty rats improves muscle insulin sensitivity by enhancing efficiency of fatty acid oxidation and acyl-glycine export. Molecular Metabolism. 5(7). 538–551. 202 indexed citations

14.

Davies, Michael N., J. Will Thompson, Laura G. Dubois, et al.. (2015). The Acetyl Group Buffering Action of Carnitine Acetyltransferase Offsets Macronutrient-Induced Lysine Acetylation of Mitochondrial Proteins. Cell Reports. 14(2). 243–254. 70 indexed citations

15.

Bernardo, Barbara, Min Lü, Gautam Bandyopadhyay, et al.. (2015). FGF21 does not require interscapular brown adipose tissue and improves liver metabolic profile in animal models of obesity and insulin-resistance. Scientific Reports. 5(1). 11382–11382. 40 indexed citations

16.

Andrews, Stuart, et al.. (1997). Duration of protective immunity against ovine haemonchosis following vaccination with the nematode gut membrane antigen H11. Research in Veterinary Science. 62(3). 223–227. 26 indexed citations

17.

Warriss, P. D., G.R. Nute, Tim Rolph, S.N. Brown, & S. Kestin. (1991). Eating quality of meat from pigs given the beta-adrenergic agonist salbutamol. Meat Science. 30(1). 75–80. 7 indexed citations

18.

Warriss, P. D., S. Kestin, Tim Rolph, & S.N. Brown. (1990). The effects of the beta-adrenergic agonist salbutamol on meat quality in pigs.. Journal of Animal Science. 68(1). 128–128. 48 indexed citations

19.

Rolph, Tim, C T Jones, & David Parry. (1982). Ultrastructural and enzymatic development of fetal guinea pig heart. American Journal of Physiology-Heart and Circulatory Physiology. 243(1). H87–H93. 32 indexed citations

20.

Jones, Colin T. & Tim Rolph. (1981). Metabolic Events Associated with the Preparation of the Fetus for Independent Life. Novartis Foundation symposium. 86. 214–233. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact